Creative Biolabs: Exploring Potential of CAR-T Therapies with Innovative Technologies

Specializing in cell and gene therapy research, Creative Biolabs enables scientists to accelerate their CAR-T cell therapies with innovative technologies and custom development and engineering services.

New York, USA – November 22, 2024 – In 2012, the use of gene-modified autologous T cells in developing CAR-T therapy to treat leukemia showed remarkable efficacy of CAR-T cell therapy against diseases. However, current CAR-T therapies have limits, and new strategies are needed to explore the potential of CAR-T cell therapies. To enhance the development of effective CAR cell therapies, Creative Biolabs has established advanced technology platforms and provides comprehensive development services to support customers’ research in this field, including allogeneic cell therapy development and in vivo cell engineering services.

Allogeneic cell therapies use cells from healthy donors, which is a promising method for changing patient access to cell-based therapies,” said a scientist from Creative Biolabs. “We recently launched a variety of allogeneic CAR-T therapy development services to provide new access for patients who are unable to undergo autologous CAR-T therapy due to factors such as poor health, inability to produce enough T cells.”

At Creative Biolabs, the allogeneic cell therapy platform is equipped with state-of-the-art facilities and advanced technology to ensure the high-quality and efficient development of allogeneic cell therapies, thereby accelerating the development of your cell therapy.

Other featured allogeneic cell therapy development services are listed below:

Allogeneic TCR-T therapy development services

Allogeneic CAR-NK therapy development services

Allogeneic CAR/TCR cell design and engineering

To fully support the advancement of CAR-T cell therapy research, Creative Biolabs also provides in vivo cell engineering services to overcome the obstacles of traditional CAR-T cell therapies.

“Our CellRapeutics™ in vivo cell engineering development services incorporate novel technologies such as CRISPR/Cas9 to integrate the vectors (viral and non-viral) and the encoded gene, then transfect the integrated vectors into the body, aiming to modify immune cells in situ,” said the scientist.

In vivo CAR-T cell engineering services provided at Creative Biolabs are highlighted by the following advantages:

Special CAR structure for in vivo CAR-T cell engineering

Modified delivery systems to aid in vivo CAR-T cell engineering

Creative Biolabs is committed to offering scientific support to enable their customers to make breakthroughs in their research. To learn more about services regarding CAR-T cell therapy, please go to https://www.creative-biolabs.com/car-t.

About Creative Biolabs

Creative Biolabs is a world-leading supplier in serving life science research and is committed to providing one-stop CAR-T cell therapy development services that help researchers and companies of all sizes advance their scientific discovery.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/car-t